Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan
© 2022. The Author(s), under exclusive licence to European Society of Human Genetics..
The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate PGx implementation by developing evidence-based pharmacogenetics guidelines to optimize pharmacotherapy. This guideline describes the starting dose optimization of the anti-cancer drug irinotecan to decrease the risk of severe toxicity, such as (febrile) neutropenia or diarrhoea. Uridine diphosphate glucuronosyl transferase 1A1 (UGT1A1 encoded by the UGT1A1 gene) enzyme deficiency increases risk of irinotecan-induced toxicity. Gene variants leading to UGT1A1 enzyme deficiency (e.g. UGT1A1*6, *28 and *37) can be used to optimize an individual's starting dose thereby preventing carriers from toxicity. Homozygous or compound heterozygous carriers of these allele variants are defined as UGT1A1 poor metabolisers (PM). DPWG recommends a 70% starting dose in PM patients and no dose reduction in IM patients who start treatment with irinotecan. Based on the DPWG clinical implication score, UGT1A1 genotyping is considered "essential", indicating that UGT1A1 testing must be performed prior to initiating irinotecan treatment.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
European journal of human genetics : EJHG - 31(2023), 9 vom: 28. Sept., Seite 982-987 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hulshof, Emma C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7673326042 |
|---|
| Anmerkungen: |
Date Completed 04.09.2023 Date Revised 11.09.2023 published: Print-Electronic CommentIn: Eur J Hum Genet. 2023 Feb 8;:. - PMID 36750665 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41431-022-01243-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349563225 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349563225 | ||
| 003 | DE-627 | ||
| 005 | 20231226042928.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41431-022-01243-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1165.xml |
| 035 | |a (DE-627)NLM349563225 | ||
| 035 | |a (NLM)36443464 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hulshof, Emma C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.09.2023 | ||
| 500 | |a Date Revised 11.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Eur J Hum Genet. 2023 Feb 8;:. - PMID 36750665 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s), under exclusive licence to European Society of Human Genetics. | ||
| 520 | |a The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate PGx implementation by developing evidence-based pharmacogenetics guidelines to optimize pharmacotherapy. This guideline describes the starting dose optimization of the anti-cancer drug irinotecan to decrease the risk of severe toxicity, such as (febrile) neutropenia or diarrhoea. Uridine diphosphate glucuronosyl transferase 1A1 (UGT1A1 encoded by the UGT1A1 gene) enzyme deficiency increases risk of irinotecan-induced toxicity. Gene variants leading to UGT1A1 enzyme deficiency (e.g. UGT1A1*6, *28 and *37) can be used to optimize an individual's starting dose thereby preventing carriers from toxicity. Homozygous or compound heterozygous carriers of these allele variants are defined as UGT1A1 poor metabolisers (PM). DPWG recommends a 70% starting dose in PM patients and no dose reduction in IM patients who start treatment with irinotecan. Based on the DPWG clinical implication score, UGT1A1 genotyping is considered "essential", indicating that UGT1A1 testing must be performed prior to initiating irinotecan treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Irinotecan |2 NLM | |
| 650 | 7 | |a 7673326042 |2 NLM | |
| 650 | 7 | |a Camptothecin |2 NLM | |
| 650 | 7 | |a XT3Z54Z28A |2 NLM | |
| 650 | 7 | |a UGT1A1 enzyme |2 NLM | |
| 650 | 7 | |a EC 2.4.1.- |2 NLM | |
| 700 | 1 | |a Deenen, Maarten J |e verfasserin |4 aut | |
| 700 | 1 | |a Nijenhuis, Marga |e verfasserin |4 aut | |
| 700 | 1 | |a Soree, Bianca |e verfasserin |4 aut | |
| 700 | 1 | |a de Boer-Veger, Nienke J |e verfasserin |4 aut | |
| 700 | 1 | |a Buunk, Anne-Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Houwink, Elisa J F |e verfasserin |4 aut | |
| 700 | 1 | |a Risselada, Arne |e verfasserin |4 aut | |
| 700 | 1 | |a Rongen, Gerard A P J M |e verfasserin |4 aut | |
| 700 | 1 | |a van Schaik, Ron H N |e verfasserin |4 aut | |
| 700 | 1 | |a Touw, Daan J |e verfasserin |4 aut | |
| 700 | 1 | |a van der Weide, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a van Westrhenen, Roos |e verfasserin |4 aut | |
| 700 | 1 | |a Deneer, Vera H M |e verfasserin |4 aut | |
| 700 | 1 | |a Guchelaar, Henk-Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Swen, Jesse J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of human genetics : EJHG |d 1996 |g 31(2023), 9 vom: 28. Sept., Seite 982-987 |w (DE-627)NLM07496920X |x 1476-5438 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2023 |g number:9 |g day:28 |g month:09 |g pages:982-987 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41431-022-01243-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2023 |e 9 |b 28 |c 09 |h 982-987 | ||